Sekisui Medical Co., Ltd.

Daiichi Pure Chemicals Co., Ltd.

Toudai Tlo, Ltd.

Other

Hiroyuki Ebinuma

Osamu Miyazaki

Yasushi Saito

Koji Ushizawa

Hideaki Bujo

Isamu Fukamachi

Takashi Kadowaki

Toshimasa Yamauchi

Hirokazu Yago

Kohei Takubo

Katsura Uchida

Masanao Matsuo

Yuka Akimoto

Kazuo Hara

Kazunori Saito

Masahiro Sekiguchi

Chiaki Nakaseko

Takuji Matsumoto

Yuriko Tsukamoto

Nobuhiro Yamada

Kumiko Yuki

Yuriko Taniguchi

Akiko Suzuki

Kengo Fujimura

Saishu Yoshida

Kyoko Tanaka

Takami Sarashina

Hirohito Sone

Osamu Myazaki

An object of the present invention is to provide a novel method for designing a primer ensuring reactivity and discriminatory power in a method for detecting a single base substitution based on an ASP-PCR method and to provide a method for easily detecting multiple point mutations within overlapping amplicons, particularly, two adjacent single base substitutions. The single base substitutions can easily be detected by using a mutant primer in which the base of the third nucleotide from the 3' end corresponds to the base of a mutant nucleotide of a single base substitution contained in a nucleic acid sample, in which the base of the second nucleotide from the 3&#x2032; end is not complementary to the base of the corresponding nucleotide of the nucleic acid, and in which the bases of the other nucleotides are complementary to the bases of the corresponding nucleotides of the nucleic acid.

Method for detecting gene mutation

Provided are a method of efficiently producing an sIL-2R antigen in an amount necessary for antibody generation, and a method of producing an anti-sIL-2R antibody using the antigen. Specifically, provided are a method of producing soluble interleukin-2 receptor, including culturing SCC-3 cells and recovering soluble interleukin-2 receptor from a culture of the cells, and a method of producing an anti-soluble interleukin-2 receptor antibody, including immunizing an animal with sIL-2R produced by the method.

Antibody for immunoassay and method for preparing same

An object of the present invention is to provide an efficient nucleic acid recovery method capable of concentrating a nucleic acid from a sample containing a nucleic acid such that the nucleic acid is usable in gene amplification reaction. To solve the problem, the present inventors have found that by targeting a protein to which a nucleic acid is bound (hereinafter also referred to as a nucleoprotein or a protein-nucleic acid complex) rather than targeting the nucleic acid itself, or specifically, by causing a specific antibody against the protein to act, the nucleic acid can be captured simultaneously with the protein, and thereby completing the present invention. Furthermore, the present inventors have found that if animal cells, bacteria, viruses, etc. have a nucleic acid bound to protein present in a cell (in an envelope in the case of viruses), the bound nucleic acid can be captured and recovered by using a specific antibody against the nucleoprotein without dissociating the nucleic acid from the protein after treating the cell with a surfactant.

Target nucleic acid concentration and recovery method using antibody

An object of the present invention is to provide a method for accurately and quantitatively discriminating and detecting a wide variety of gene mutations, or particularly, single base substitutions or point mutations. In an ASP for analyzing gene mutations, or particularly, single base substitutions or point mutations, when a non-nucleotide component is added to the 5' end of at least one of the ASP and a primer paired therewith before amplification by PCR and amplification products thereof are separated by ion-exchange chromatography, even the amplification products having the same length can be separated and detected.

Method for detecting single base substitution using ion-exchange chromatography

Provided is a detection method for a malignant tumor cell, including measuring a protein marker expressed on a malignant tumor cell surface. The detection method for a malignant tumor cell includes measuring LR11 on a cell surface in a sample to be tested.

Method for detecting malignant tumor cells

To provide a method for assaying soluble LR11 in a biological sample, which method realizes a simple and accurate assay of soluble LR11 present in the sample by immunological means without requiring isolation of soluble LR11 from the biological sample (e.g., a serum sample). The method of the invention for immunologically assaying soluble LR11 present in a biological sample, characterized in that the method includes treating the sample with at least one surfactant selected from among one or more sulfobetaine amphoteric surfactants and one or more amidosulfobetaine amphoteric surfactants.

Method for immunologically measuring soluble LR11

Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin.

High-molecular-weight adiponectin measurement method

Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid.

Method for quantification of soluble LR 11

To provide a method and a diagnostic kit for determining the presence of a malignant tumor or the severity thereof, a method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or a method for estimating the risk of recurrence of the malignant tumor or determining the presence or absence of the recurrence. The method for determining the presence of a malignant tumor or the severity thereof, method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or method for estimating the risk of recurrence of the malignant tumor or the presence or absence of the recurrence is characterized by including 1) a step of measuring the concentration and/or quantity of soluble LR11 in a sample originating from a subject and 2) a step of comparing the value measured above with a measurement value of soluble LR11 obtained from a healthy subject group.

Method for diagnosing malignant tumor

Kits and methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and/or an antibody.

Method of selectively assaying adiponectin multimers

The present invention provides a convenient, efficient method for assaying glycated protein, fructosyl peptide, or fructosyl amino acid which can be performed with reduced effect of fructosyl lysine compounds. The invention also provides a reagent for the assay. The invention is directed to a method for reducing the effect of a fructosyl lysine compound in an assay of fructosyl peptide or fructosyl amino acid contained in a sample, characterized by including causing an enzyme for assaying fructosyl peptide or fructosyl amino acid to act specifically on fructosyl peptide or fructosyl amino acid at a pH of 4.0 to 7.0 and measuring the product at a pH of 4.0 to 7.0; and a method for assaying glycated protein through the above method.

Method of assaying glycated protein

The present invention is directed to a monoclonal antibody against a soluble fibrin, which specifically recognizes a conformation-changed site newly occurred in a C-terminal region of an A&#x3b1;-chain of the soluble fibrin formed through thrombin digestion of fibrinogen. The present invention is also directed to a hybridoma which produces the antibody, an immunological assay method employing the antibody, and a method for evaluating hypercoagulability in a test sample by measuring the soluble fibrin level in the sample with the assay method. Through employment of the monoclonal antibody of the present invention, soluble fibrin on which plasmin has not acted, which reflects exclusively initial hypercoagulability, can be specifically detected.

Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody

The invention provides a method of pretreating a sample for conveniently, quickly and accurately measuring the total amount of adiponectin present in a biological sample contaminated with various adiponectin multimers. The method of measuring an sample for immunologically assaying the total amount of adiponectin present in the sample comprises reacting, with an adiponectin-containing sample, at least one of a reducing agent, an acid or a salt thereof, a surfactant, and a protease.

Mehod of pretreating sample and immunological assay method using the same

Methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying of a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and/or an antibody.

A method for quantitatively determining a specific component in a biological specimen, which includes reacting a biological specimen, in the presence of an electron acceptor, with an enzyme which has an ability, by the dehydrogenation reaction, to oxidize the specific component or a substance derived from the specific component, and measuring the formed reductant of the electron acceptor, wherein the method avoids the influence of hemoglobin effectively if any contained in the specimen by using a measuring reagent containing albumin, thereby making an quantitative determination of the target component accurately; and a reagent for the quantitative determination.

Growing community of inventors

Ryugasaki, Japan

Hiroyuki Ebinuma